- Report
- April 2020
- 75 Pages
Global
From €3753EUR$3,950USD£3,218GBP
- Report
- April 2020
- 80 Pages
Global
From €3753EUR$3,950USD£3,218GBP
- Report
- April 2020
- 75 Pages
Global
From €3753EUR$3,950USD£3,218GBP
- Drug Pipelines
- March 2020
- 100 Pages
Global
From €3088EUR$3,250USD£2,648GBP
- Report
- April 2024
- 180 Pages
From €4655EUR$4,900USD£3,992GBP
- Report
- October 2023
- 89 Pages
India
From €3325EUR$3,500USD£2,851GBP
- Report
- September 2019
- 71 Pages
Global
€2845EUR$2,995USD£2,440GBP
- Drug Pipelines
- September 2019
- 141 Pages
Global
€9500EUR$10,000USD£8,146GBP
- Report
- November 2018
- 80 Pages
Global
From €2850EUR$3,000USD£2,444GBP
- Report
- October 2021
- 131 Pages
Global
From €10446EUR$10,995USD£8,957GBP
- Report
- September 2021
- 126 Pages
Global
From €10446EUR$10,995USD£8,957GBP
- Report
- March 2020
- 141 Pages
Global
From €7595EUR$7,995USD£6,513GBP
- Report
- March 2021
- 77 Pages
Global
€20901EUR$22,000USD£17,922GBP
- Report
- October 2020
- 85 Pages
Global
€20901EUR$22,000USD£17,922GBP
- Report
- April 2023
- 326 Pages
Global
From €3420EUR$3,600USD£2,933GBP
- Report
- February 2022
- 185 Pages
Global
From €3420EUR$3,600USD£2,933GBP
- Report
- February 2022
- 92 Pages
Middle East, Africa
From €1425EUR$1,500USD£1,222GBP
- Report
- February 2022
- 93 Pages
Asia Pacific
From €1425EUR$1,500USD£1,222GBP
- Report
- February 2022
- 91 Pages
Europe
From €1425EUR$1,500USD£1,222GBP
- Report
- February 2022
- 83 Pages
North America
From €1425EUR$1,500USD£1,222GBP
Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more